Insight Molecular Diagnostics Inc. — Director's Dealing 2018

Sep 4, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2018-08-30

Reporting Person: Last Andrew J. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-30	Option to Purchase Common Stock	$2.40	A	45000	Acquired	2028-08-29	Common Stock (45000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	6993	Direct

Footnotes

F1: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.